Intrauterine growth retardation

J O Gardosi1, J M Mongelli, T Mul

  • 1Department of Obstetrics and Gynaecology, Queen's Medical Centre, Nottingham, UK.

Bailliere'S Clinical Obstetrics and Gynaecology
|September 1, 1995
PubMed

IUGR puts the fetus at risk of stillbirth, perinatal morbidity and neonatal handicap, yet most instances of IUGR are not recognized. Progress has been made in recent years to monitor the high-risk fetus with intensive biometric and biophysical tests and to determine the appropriate time for intervention. These methods of surveillance are ineffective and inappropriate for population screening, and the main problem remains how to identify the at-risk fetus. Improvement of current performance requires the establishment of appropriate standards by which intrauterine growth can be assessed, and their introduction as part of well-organized screening programmes. We describe a computerized method of predicting the optimal weight for each pregnancy, which is individually adjusted for non-pathological variables such as maternal height, booking weight, ethnic group and parity. The optimal birthweight determines the expected slope or velocity of fetal weight gain. This individualized prediction improves the distinction between constitutional and pathological smallness. Furthermore, preterm weights are measured against a fetal weight norm rather than a birthweight standard that is derived from non-physiological preterm deliveries. The customized growth chart allows screening for growth retardation by determining the growth velocity through serial measurement and plotting of fundal height, backed up as necessary by ultrasound estimation of fetal weight and referral for more intensive surveillance as indicated.

Related Concept Videos

Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
In Vitro Fertilization01:24

In Vitro Fertilization

In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...